Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Chronic beryllium disease: a model interaction between innate and acquired immunity.

Authors
Sawyer-RT; Maier-LA; Kittle-LA; Newman-LS
Source
Int Immunopharmacol 2002 Feb; 2(2-3):249-261
NIOSHTIC No.
20024241
Abstract
Beryllium (Be) is a lightweight and durable metal useful to a variety of manufacturing processes. With the use of Be in industrial settings, a number of health effects were noted including acute pneumonitis, sensitization to Be, interstitial lung disease and dermatological disease. Interstitial mononuclear cell inflammation and granuloma formation are the primary processes that occur in the lungs of Be-exposed workers, resulting in chronic beryllium disease (CBD). Recent studies have begun to describe the role of Be in the pathogenesis of CBD. These studies reveal that the host's response to Be involves components of the innate immune system or inflammatory responses. Inflammatory responses to Be can establish a state of acquired, Be antigen-specific, cell-mediated immunity. Despite triggering both the innate and acquired immune responses, Be is not eliminated from the host. Rather, it establishes pathways leading to chronic granulomatous inflammation. We will examine recent studies describing the host's cellular and molecular responses to Be, responses that promote granuloma formation.
Keywords
Beryllium-compounds; Beryllium-disease; Immune-reaction; Immune-system; Immunology; Chronic-exposure; Chronic-inflammation; Cellular-reactions; Lung-cells; Lung-disorders
Contact
National Jewish Medical and Research Center, Department of Medicine, 1400 Jackson Street, Denver, CO 80206
CAS No.
7440-41-7
Publication Date
20020201
Document Type
Journal Article
Email Address
sawyerr@njc.org
Funding Amount
1980104
Funding Type
Cooperative Agreement
Fiscal Year
2002
NTIS Accession No.
NTIS Price
Identifying No.
Cooperative-Agreement-Number-U60-CCU-812221
Issue of Publication
2-3
ISSN
1567-5769
Source Name
International Immunopharmacology
State
CO
Performing Organization
National Jewish Medical and Research Center, Department of Medicine, Denver, Colorado 80206
TOP